



## PRIOR AUTHORIZATION REQUEST

### Rivfloza

#### Patient Information:

|                   |  |
|-------------------|--|
| Name:             |  |
| Member ID:        |  |
| Address:          |  |
| City, State, Zip: |  |
| Date of Birth:    |  |

#### Prescriber Information:

|                   |  |
|-------------------|--|
| Name:             |  |
| NPI:              |  |
| Phone Number:     |  |
| Fax Number:       |  |
| Address:          |  |
| City, State, Zip: |  |

#### Requested Medication

|                             |  |
|-----------------------------|--|
| Rx Name:                    |  |
| Rx Strength:                |  |
| Rx Quantity:                |  |
| Rx Frequency:               |  |
| Rx Route of Administration: |  |
| Diagnosis and ICD Code:     |  |

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

**SECTION A:** Please note that supporting clinical documentation is required for ALL PA requests. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

|   |  |     |    |
|---|--|-----|----|
| 1 | Is the patient currently receiving the requested medication?<br>[If no, skip to question 7.]   | Yes | No |
| 2 | Has the patient been receiving medication samples of Rivfloza?<br>[If yes, skip to question 7.]  | Yes | No |
| 3 | Does the patient have a previously approved prior authorization (PA) on file with the current plan for Rivfloza?<br>[Note: If the patient does NOT have a previously approved PA on file for the | Yes | No |

If you have any  
questions, call:  
1-888-258-8250

Version 07.2025

## PRIOR AUTHORIZATION REQUEST

requested medication with the current plan, the renewal request will be considered under initial therapy.]

[If no, skip to question 7.]

- |    |  |     |    |
|----|--|-----|----|
| 4  | Has the patient been established on therapy for at least 3 months?<br>[If no, skip to question 7.]   | Yes | No |
| 5  | Has documentation been submitted to confirm that the patient has had a clinically significant response to therapy, as determined by the provider? ACTION REQUIRED: Submit supporting documentation.<br>[If no, no further questions.]  | Yes | No |
| 6  | Is the requested medication prescribed by or in consultation with a nephrologist, urologist, or specialist with expertise in the treatment of primary hyperoxaluria?<br>[No further questions.]  | Yes | No |
| 7  | What is the indication or diagnosis?<br><input type="checkbox"/> Primary hyperoxaluria Type 1 (If checked, go to 8)<br><input type="checkbox"/> Other (If checked, no further questions)   |     |    |
| 8  | Has documentation been submitted to confirm the diagnosis with genetic testing of a confirmed mutation in the alanine:glyoxylate aminotransferase (AGXT) gene or a liver enzyme analysis demonstrating absent or significantly reduced alanine:glyoxylate aminotransferase (AGT) activity? ACTION REQUIRED: Submit supporting documentation.<br>[If no, no further questions.] | Yes | No |
| 9  | Is the patient 9 years of age or older?<br>[If no, no further questions.]  | Yes | No |
| 10 | Does the patient have preserved kidney function with an estimated glomerular filtration rate of at least 30 mL/min (eGFR greater than or equal to 30 mL/min/1.73 m2)?<br>[If no, no further questions.]  | Yes | No |
| 11 | Has the patient received a kidney or liver transplant?<br>[If yes, no further questions.]  | Yes | No |
| 12 | Has documentation been submitted to show that the patient has a urinary oxalate excretion greater than or equal to 0.7 mmol/24 hours/1.73 m2 in age less than 18 years based on at least 2 assessments? ACTION REQUIRED: Submit supporting documentation.<br>[If yes, skip to question 15.]  | Yes | No |
| 13 | Has documentation been submitted to show that the patient has a spot urinary oxalate: creatinine ratio above the age specific upper limit of normal? ACTION REQUIRED: Submit lab reference range.  | Yes | No |

**If you have any  
questions, call:  
1-888-258-8250**

Version 07.2025



## PRIOR AUTHORIZATION REQUEST

[If yes, skip to question 15.]

- |    |  |     |    |
|----|--|-----|----|
| 14 | Has documentation been submitted to show an elevated plasma oxalate concentration greater than the upper limit of normal? ACTION REQUIRED: Submit lab reference range.<br>[If no, no further questions.]   | Yes | No |
| 15 | Will the patient be taking the requested medication in combination with Oxlumo?<br>[If yes, no further questions.]   | Yes | No |
| 16 | Has documentation been submitted to show that the patient had a trial and failure (of at least 3 months) on optimal dose, intolerance to, or contraindication to pyridoxine? ACTION REQUIRED: Submit supporting documentation.<br>[If no, no further questions.] | Yes | No |
| 17 | Is the patient inadequately managed with increased fluid intake (hyperhydration)?<br>[If no, no further questions.]  | Yes | No |
| 18 | Is the requested medication prescribed by or in consultation with a nephrologist, urologist, or specialist with expertise in the treatment of primary hyperoxaluria?<br>[If no, no further questions.]   | Yes | No |
| 19 | Is the dosing within the Food and Drug Administration (FDA) approved labeling?   | Yes | No |

***Please document the diagnoses, symptoms, and/or any other information important to this review:***

### **SECTION B:** Physician Signature

PHYSICIAN SIGNATURE

DATE

**FAX COMPLETED FORM TO: 1-833-896-0656**

**Disclaimer:** An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**Confidentiality:** The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

**If you have any  
questions, call:  
1-888-258-8250**

Version 07.2025